Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study) - 82% off b/tsDMARDs at 12mo - also with benefit to control group after crossover at 3mo to an active device #ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF

• https://x.com/drdavidliew/status/1982878593199026656/photo/1

Did we need a 2nd Interception RCT of HCQ in Pre-RA? Unsure but in any case, it does not work either STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO 36 months RA conversion Dr Deane's take: "probably wrong drug rather than wrong timing" #ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v

• https://x.com/AurelieRheumo/status/1982874833257152964/photo/1

#ACR25 SMILE RCT of Incomplete #SLE (ANA+ but not meeting SLICC) showed HCQ didn’t slow down SLE progression. But multiplex arrays showed reduction in autoantibodies with HCQ that were distinct from abs assoc. w progression. Would biomarker endpoints be the answer? @RheumNow https://t.co/XcvacgObVo

• https://x.com/Yuz6Yusof/status/1982864787144093994/photo/1

In a cohort of 269,304 IBD patients, NSAID use showed a small increase in IBD-related hospitalisation (HR 1.08), meeting non-inferiority threshold (HR <1.2). No risk in UC (HR 0.96); modest risk in Crohn’s (HR 1.16). Relooks at the current paradigm of blanket NSAID avoidance in https://t.co/O8MWg1BP50

• https://x.com/synovialjoints/status/1982862356670480474/photo/1

56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation Leflunomide protective? Have others seen this? #ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv

• https://x.com/EBRheum/status/1982860846771437709/photo/1

Sun et al. Telitacicept in SARD-ILD (pSS, ASS, RA). 25 patients. Improvements in CT, PFTs, 6MWT. @RheumNow #ACR25 Abstr#1361 https://t.co/q679LOaOyL

• https://x.com/RichardPAConway/status/1982857071872622948/photo/1

In pooled analysis of 9 PsA trials, 6.9% of secukinumab-treated patients had fungal infections, mostly mild/moderate. Candida rates were low (1.86–2.18/100 PY) and didn’t increase over time. 89.7% resolved fully; only 0.8% led to discontinuation. Abstract 1459 @RheumNow #ACR25 https://t.co/kltMZVEDf9

• https://x.com/synovialjoints/status/1982854810463260751/photo/1

England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta

• https://x.com/RichardPAConway/status/1982854555105947705/photo/1

Interim analysis of Ph3 TULIP-SC trial: Anifrolumab 120mg SC or PBO weekly + SOC x 52wks Primary endpt met: BICLA response w/Anifrolumab (60.3%) vs. PBO(43.9%)[p=0.014] Pts on Ani had sustained BICLA response upto wk 52 (HR 2.1) Promising results. #ACR25 @RheumNow Abs1545 https://t.co/nqse1BiGq2

• https://x.com/RHEUMarampa/status/1982853044934225957/photo/1
• https://x.com/RHEUMarampa/status/1982853044934225957/photo/1

In Sjögren’s, cancer risk is real. >9yr multicenter cohort (n=314), overall cancer risk ↑ (SIR 1.68), NHL >15× expected Predictors: older age, smoking, LAD, splenomegaly, cryoglobulinemia (strongest for lymphoma). Malignancies = 24% of deaths @RheumNow #ACR25 Abstract #1681

Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE

• https://x.com/RichardPAConway/status/1982845746950164581/photo/1

In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al, Bet. wks 24 and 76: Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074) Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039) Addtl tx option for LN #ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E

• https://x.com/RHEUMarampa/status/1982844740291952655/photo/1

Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43 Ongoing research, further data needed. #ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW

• https://x.com/RHEUMarampa/status/1982843734011105721/photo/1

Infection data from SELECT-GCA: Glucocorticoids seem to drive overall infectious risk UPA use associated with higher zoster - vaccinate!! @RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q

• https://x.com/Dr_Brian_MD/status/1982843521112641587/photo/1

Prednisone remains both lifeline and liability. New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict. @RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p

• https://x.com/JihaRheum/status/1982842223743164901/photo/1